- Report
- February 2024
- 70 Pages
Philippines
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
India
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 181 Pages
Europe
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
United States
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Spain
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Iran
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Australia
From €4460EUR$4,750USD£3,721GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1878EUR$2,000USD£1,567GBP
- Report
- September 2022
- 30 Pages
Global
From €2582EUR$2,750USD£2,154GBP
- Report
- May 2026
- 200 Pages
Canada
From €2619EUR$2,789USD£2,185GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2619EUR$2,789USD£2,185GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2619EUR$2,789USD£2,185GBP
- Report
- June 2025
- 250 Pages
United States
From €2619EUR$2,789USD£2,185GBP
- Report
- June 2025
- 300 Pages
Europe
From €3633EUR$3,869USD£3,031GBP
- Report
- June 2025
- 400 Pages
Global
From €4647EUR$4,949USD£3,877GBP
- Report
- May 2025
- 300 Pages
Global
From €4647EUR$4,949USD£3,877GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more